Acute Coronary Syndrome – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of acute coronary syndrome (ACS) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report both the diagnosed incidence and prevalence of ACS in each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s ACS forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of ACS?
- How will improvements in survival change the number of people living with a diagnosis of ACS?
- Of all people diagnosed with ACS, how many in each country are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ACS over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 24 ACS patient populations, as follows:
- Diagnosed events of ACS.
- Diagnosed events of ACS by subtype (STEMI / NSTEMI / UA).
- Diagnosed events of ACS by drug-treatment status.
- 12-month diagnosed prevalent cases of ACS.
- 12-month diagnosed prevalent cases of ACS by subtype (STEMI / NSTEMI / UA).
- Diagnosed lifetime prevalent cases of ACS.
- Diagnosed events of ACS with a history of myocardial infarction (MI).
- Diagnosed events of ACS with a history of stroke.
- Diagnosed events of ACS with hypertension.
- Diagnosed events of ACS with hyperlipidemia.
- Diagnosed events of ACS with diabetes mellitus.
- Diagnosed events of ACS with atrial fibrillation.
- Diagnosed events of ACS with heart failure.
Note: Coverage may vary by country.
Table of contents
- Acute Coronary Syndrome - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of acute coronary syndrome)
- Diagnosed events
- Diagnosed events by subtype
- Drug-treated events
- 12-month diagnosed prevalent cases
- 12-month diagnosed prevalent cases by subtype
- Lifetime diagnosed prevalent cases
- Diagnosed events with atrial fibrillation
- Diagnosed events with a history of myocardial infarction
- Diagnosed events with a history of stroke
- Diagnosed events with heart failure
- Diagnosed events with hyperlipidemia
- Diagnosed events with hypertension
- Diagnosed events with diabetes mellitus
- Risk / protective factors applied to disease forecast models
- Reference Materials
